Innovent Gains China Commercialization Rights for VANFLYTA
Innovent Biologics and Daiichi Sankyo entered an exclusive agreement for commercialization of VANFLYTA (quizartinib) in China. Innovent will hold sole commercialization rights and lead market promotion, while Daiichi Sankyo retains development, manufacturing and supply…
